The continued spread of multidrug-resistant (MDR) tuberculosis and extensively drug-
resistant tuberculosis poses a major threat to global tuberculosis control. Treatment is …

Tuberculosis (TB) is still a major global health problem. A third of the world's population is
infected with Mycobacterium tuberculosis. Only~ 10% of infected individuals develop TB but …

Tuberculosis (TB) is a serious public health problem worldwide. The combination of various
anti-TB drugs is mainly used to treat TB in clinical practice. Despite the availability of …

Currently available chemotherapy for the treatment of pulmonary tuberculosis (TB) is far from
ideal, requiring multiple anti-tuberculous drugs to be taken in combination for extended time …

Drug treatment is the key strategy in TB control. However, the treatment course lasts 6–9
months because the current anti-TB drugs are poorly effective against nondividing (ie …

Globally, tuberculosis (TB) rates have started to decline, including in sub-Saharan Africa,
apart from South Africa and Lesotho. In high human immunodeficiency virus (HIV)-prevalent …

TB is typically caused by Mycobacterium tuberculosis, a symbiotic bacterium present in one-
third of the world's population. There any many factors triggering overt clinical disease in a …

[Frontiers in Bioscience 17, 2684-2690, June 1, 2012] 2684 Immunotherapy for Tuberculosis:
what’s the better choice? Shuliang Page 1 [Frontiers in Bioscience 17, 2684-2690, June 1, 2012] …

Abstract Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults
comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases …

The increasing threat posed by drug-resistant strains of M. tuberculosis is leading to a
reappraisal of the possibility of treating tuberculosis (TB) by immunotherapy. We analyze 6 …